Oral treatments for Non-Small Cell Lung Cancer

The phrase "oral treatments for non-small cell lung cancer" is not a formal or discrete pharmacological drug class recognized by regulatory agencies like the FDA or NCI, but rather an administrative grouping describing orally administered antineoplastic agents indicated for non-small cell lung cancer

The phrase "oral treatments for non-small cell lung cancer" is not a formal or discrete pharmacological drug class recognized by regulatory agencies like the FDA or NCI, but rather an administrative grouping describing orally administered antineoplastic agents indicated for non-small cell lung cancer This broad category predominantly comprises small-molecule targeted therapies—principally tyrosine kinase inhibitors and related molecular inhibitors targeting alterations such as EGFR, ALK, ROS1, B...

This broad category predominantly comprises small-molecule targeted therapies—principally tyrosine kinase inhibitors and related molecular inhibitors targeting alterations such as EGFR, ALK, ROS1, BRAF, RET, MET, KRAS, and HER2—as well as select oral chemotherapeutic agents Clinically, they are used across early-stage adjuvant, locally advanced, and metastatic non-small cell lung cancer regimens matching specific genomic or clinical profiles

This broad category predominantly comprises small-molecule targeted therapies—principally tyrosine kinase inhibitors and related molecular inhibitors targeting alterations such as EGFR, ALK, ROS1, BRAF, RET, MET, KRAS, and HER2—as well as select oral chemotherapeutic agents

These agents function mechanistically by selectively disrupting intracellular oncogenic signaling cascades or inhibiting cell division to arrest tumor proliferation and induce apoptosis